Advanced or Metastatic nivolumab (flat dosing) |
Low |
August 2024 |
Advanced, metastatic or recurrent pembrolizumab |
Low |
August 2024 |
Non small cell lung cancer adjuvant ciSplatin and pemetrexed |
Medium |
August 2024 |
Non small cell lung cancer adjuvant cISplatin and vinORELBine |
Medium |
August 2024 |
Non small cell lung cancer adjuvant osimertinib3 |
Low |
August 2023 |
Non small cell lung cancer definitive cISplatin and etoposide chemoradiation |
Medium |
August 2024 |
Non small cell lung cancer locally advanced definitive cARBOplatin and PACLitaxel chemoradiation |
Medium |
February 2024 |
Non small cell lung cancer locally advanced durvalumab — weight based dosing (following chemoradiation) |
Low |
August 2024 |
Non small cell lung cancer locally advanced durvalumab — flat dosing (following chemoradiation) interim protocol (PDF 442KB)
|
Low |
November 2023 |
Non small cell lung cancer locally advanced or metastatic alectinib |
Low |
August 2024 |
Non small cell lung cancer locally advanced or metastatic atezolizumab |
Low |
August 2024 |
Non small cell lung cancer locally advanced or metastatic brigatinib |
Low |
February 2024 |
Non small cell lung cancer locally advanced or metastatic cARBOplatin and gemcitabine |
Medium Day 1. Low day 8 |
August 2024 |
Non small cell lung cancer locally advanced or metastatic cARBOplatin and PACLItaxel |
Medium |
August 2024 |
Non small cell lung cancer locally advanced or metastatic cARBOplatin and pemetrexed |
Medium |
August 2025 |
Non small cell lung cancer locally advanced or metastatic cARBOplatin and vinORELBine |
Medium |
August 2024 |
Non small cell lung cancer locally advanced or metastatic cARBOplatin and weekly PACLItaxel |
Medium |
February 2024 |
Non small cell lung cancer locally advanced or metastatic osimertinib |
Low |
August 2024 |
Non small cell lung cancer locally advanced or metastatic sotorasib3 |
Low |
August 2023 |
Non small cell lung cancer locally advanced or metastatic tepotinib3 (available via medicines access program) |
Low |
August 2023 |
Non small cell lung cancer metastatic afatinib |
Low |
August 2022 |
Non small cell lung cancer metastatic cARBOplatin PACLitaxel and pembrolizumab |
Medium. (moves to low risk after completion of cARBOplatin/PACLitaxel treatment) |
August 2024 |
Non small cell lung cancer metastatic cARBOplatin PACLitaxel atezolizumab and bevacizumab |
Medium (moves to low risk after completion of cARBOplatin/PACLitaxel treatment) |
August 2023 |
Non small cell lung cancer metastatic cARBOplatin PACLitaxel ipilimumab and nivolumab |
Medium |
August 2024 |
Non small cell lung cancer metastatic cARBOplatin, pemetrexed and pembrolizumab |
Medium |
August 2024 |
Non small cell lung cancer metastatic gemcitabine |
Low |
August 2024 |
Non small cell lung cancer locally advanced or metastatic cISplatin and gemcitabine |
Medium Day 1. Low Day 8 |
August 2024 |
Non small cell lung cancer locally advanced or metastatic cISplatin and pemetrexed |
Medium |
August 2024 |
Non small cell lung cancer locally advanced or metastatic cISplatin and vinORELBine |
Medium |
August 2024 |
Non small cell lung cancer locally advanced or metastatic entrectinib |
Low |
August 2024 |
Non small cell lung cancer locally advanced or metastatic lorlatinib |
Low |
August 2024 |
Non small cell lung cancer metastatic ciSplatin, pemetrexed and pembrolizumab |
Medium |
August 2024 |
Non small cell lung cancer metastatic DOCEtaxel three weekly |
Medium |
August 2024 |
Non small cell lung cancer metastatic pemetrexed |
Low1 |
February 2024 |
Non small cell lung cancer metastatic vinORELBine (intravenous). The SA Health Cancer Drug Committee endorses the substitution of oral vinORELBine for this single agent protocol for suitable patients |
Medium |
August 2024 |
Non small cell lung cancer metastatic vinORELBine (oral) |
Low |
August 2024 |
Non small cell lung cancer superior sulcus (Pancoast) cISplatin and etoposide chemoradiation pre-operative |
Medium |
February 2024 |